Antibodies for Coronavirus Research
The recent pandemic has caused a global effort to rapidly characterize SARS-CoV-2, the virus responsible for COVID-19, as well as develop potential treatments for the disease and create a vaccine to halt viral transmission. This substantial effort requires the right tools, resources, and support to make progress. Bio-Techne is a leader in the life science industry and offers workflow solutions for SARS-CoV-2 and COVID-19 research. A large part of our offerings includes R&D Systems highly validated and specific antibodies. Our antibodies are being used for several areas of SARS-CoV-2 research including investigation of viral recognition and characterization of the immune response following SARS-CoV-2 infection.
Explore our antibodies and related resources to find the rights tools to support and accelerate your Coronavirus research. For more information on all of Bio-Techne’s products for investigating SARS-CoV-2, including immunoassays, small molecules, cell culture products, and more, visit our Tools for Coronavirus page. Can’t find what you need? Fill out our product suggestion form, located at the bottom of the page, to provide input into what new COVID-19-related antibodies should be released next.
Researching the Omicron Variant?
Find antibodies to detect and block the Omicron variant of SARS-CoV-2 Spike protein (blocking, Cat # MAB105405).
Antibodies for Detecting SARS-CoV-2
Ending the COVID-19 pandemic and controlling the spread of SARS-CoV-2 infection requires having diagnostic tools that can accurately detect the virus, as well as therapies that can treat COVID-19, and perhaps, prevent viral infection. To help develop these tools, R&D systems offers antibodies that can be used for a variety of applications including identifying those cells susceptible to SARS-CoV-2 infection or assessing assay performance during development.
Antibodies for Investigating Viral Recognition by SARS-CoV-2
A key mechanism of SARS-CoV-2 infection is the binding of the coronavirus to the cell surface receptor ACE-2. This important step in viral recognition is a major target for therapeutic development. R&D Systems offers antibodies directed against virus and host cell molecules involved in viral infection, such as ACE-2 and SARS-CoV-2 proteins, that can be used to characterize protein expression or as a control for assessing the effectiveness of newly developed therapeutics.
Blocking Antibodies for SARS-CoV-2, ACE-2 and More
A major step in developing therapeutics to block SARS-CoV-2 infection involves determining the neutralization efficacy of the potential biologics or small molecules. R&D Systems offers a selection of blocking antibodies directed against SARS-CoV-2, ACE-2, and other viral and host cell antigens that can be used as controls in SARS-CoV-2 blocking/neutralization assays.
Antibodies for SARS-CoV-2 Immunoassay Development
Health experts have called for the broad screening of individuals for SARS-CoV-2 infection in order to help control the spread of this virus. However, the diagnostic tests currently used have several limitations, making them less than ideal for mass testing. There is a need to develop tests that are quick to run and easy to use, such as Lateral Flow Immunoassays (LFIAs). R&D Systems offers high-affinity SARS-CoV-2 antibodies for immunoassay development.
Antibodies for Characterizing SARS-CoV-2-Induced Immune Responses
The immunopathogenesis of SARS-CoV-2 infection continues to be a major focus of COVID-19 research as defining the contributions of immune responses in COVID-19 disease progression and severity is necessary to advance the development of therapies that regulate dysfunctional immune responses. R&D Systems offers antibodies for characterizing immune responses induced by SARS-CoV-2 infection.
Key SARS-CoV-2 Citations Utilizing R&D Systems Antibodies
Since publication of the pivotal papers at the beginning of 2020 by Zhou, J. et al.and Hoffmann, M. et al., which used our ACE-2 antibody to show that SARS-CoV-2 uses this cell surface receptor to infect cells, our antibodies have been used in a broad range of COVID-19 research. Explore these key SARS-CoV-2 and COVID-19 related citations to see how our antibodies are being used to advance COVID-19 research.
Publication Spotlight
A newly released preprint study suggested that investigation of ACE-2 protein expression has been lacking due to the unreliable specificity of most commercial ACE-2 antibodies. Authors of the study independently validated 13 ACE-2 antibodies for flow detection of ACE-2 to study cellular heterogeneity of its expression. The authors determined that of the 13 antibodies tested, only two, R&D Systems Goat Anti-Human/Mouse/Rat/Hamster ACE-2 Antigen Affinity-Purified Polyclonal Antibody (Catalog # AF933) and Mouse Anti-Human/Rat/Hamster ACE-2 Monoclonal Antibody (Catalog # MAB9332), showed specific ACE-2 detection. The other 11 antibodies did not exhibit any staining above background or had staining that was not affected by ACE-2 overexpression or deletion.
- Alexpandi, R. et al. (2020) Quinolines-based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 inhibitor for drug-repurposing against COVID-19: an in silico analysis. Front. Microbiol. 11:1796.
- Bilinska, K. et al. (2020) Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium: identification of cell types and trends with age. ACS Chem. Neurosci. 11:1555.
- Crawford, K.H.D. et al. (2020) Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses 12:513.
- Collin, J. et al. (2020) Co-expression of SARS-CoV-2 entry genes in the superficial adult human conjunctival, limbal and corneal epithelium suggests and additional route of entry via the ocular surface. Ocul. Surf. [Epub ahead of print].
- Fignani, D. et al. (2020) SARS-CoV-2 receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) is expressed in human pancreatic β-cells and in the human pancreas microvasculature. Front. Endocrinol. 11:596898.
- Hikmet, F. et al. (2020) The protein expression profile of ACE2 in human tissues. Mol. Syst. Biol. 16:e9610.
- Hoffmann, M. et al. (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is Blocked by a Clinically Proven Protease Inhibitor. Cell 181:271.
- Lamers, M.M. et al. (2020) SARS-CoV-2 productively infects human gut enterocytes. Science. 369:50.
- Monteil, V. et al. (2020) Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. 181:905.
- Ou, X. et al. (2020) Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nature Comm. 11:1620.
- Sherman, E.J. and Emmer, B.T. (2021) ACE2 protein expression within isogenic cell lines is heterogeneous and associated with distinct transcriptomes. bioRxiv doi: 10.1101/2021.03.26.437218.
- Sun, J. et al. (2020) Generation of a broadly useful model of COVID-19 pathogenesis, vaccination, and treatment. Cell 182:734.
- Tai, W. et al. (2020) Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell. Mol. Immunol. 17:613.
- Wang, J. et al. (2020) The ACE2-deficient mouse: a model for a cytokine storm-driven inflammation. FASEB J. [Epub ahead of print].
- Xia, S. et al. (2020) Long term culture of human kidney proximal tubule epithelial cells maintains lineage functions and serves as an ex vivo model for coronavirus associated kidney injury. Virol. Sin. 35:311.
- Zhang, L. et al. (2020) SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat. Comm. 11:6013.
- Zhang, Q. et al. (2020) Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 370:eabd4570.
- Zhou, J. et al. (2020) Infection of bat and human intestinal organoids by SARS-CoV-2. Nat. Med. 26:1077.
- Ziegler, C. G. K. et al. (2020) SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181:1016.
Additional Resources for Coronavirus Research
On-Demand COVID-19-Related Webinars
COVID-19 Symposium: Research Tools from Bio-Techne
This webinar discusses the broad range of tools Bio-Techne has developed to help researchers investigate COVID-19. Learn how our proteins, antibodies, small molecules, and other product lines, such as RNAscope® and automated protein analysis platforms can help propel your research.
Monitoring the Interaction of SARS-CoV-2 with ACE-2 and the Resulting Immune Response with Flow Cytometry
This webinar describes the utility of flow cytometry to investigate the interaction of SARS-CoV-2 with ACE-2 on the host cell. Learn how our flow cytometry-validated antibodies can be used for ACE-2 detection and in an in vitro flow cytometry-based ACE-2/SARS-Cov-2 blocking assay.
Articles
ACE-2: The Receptor for SARS-CoV-2
This article reviews the seminal papers that were published at the beginning of the COVID-19 pandemic that uncovered how SARS-CoV-2 infects host cells
New COVID-19 Research Product Suggestion
Help us deliver the COVID-19 research products you want. Fill out the form below to provide input into what new antibody products we release next.
Featured Content
Omicron Blocking Antibodies
SARS CoV-2 Spike S1 Subunit Antibody (Blocking, Cat # MAB105405)
SARS-CoV-2 Reagents from Novus Biologicals
Explore Novus Biologicals proteins and antibodies for COVID-19 research.
New COVID-19 Detection Test Offering
Collection occurs from convenience of home. Don't wait. Get checked now. Available to all 50 states.
LlaMABody™ Products
Take advantage of the small size of camelid antibodies to detect hard to reach epitopes with our new LlaMABody products.
Ella
Measure the inflammatory response during COVID-19 in real time with Ella
Proteins for Coronavirus Research
SARS-CoV-2 Proteins, ACE-2, DPPIV, Aminopeptidase N